Brought to you by 
Adimab raises $6.2mm in Series A round
25 Jun 2009
Executive Summary
Adimab (yeast-derived antibodies) raised $6.2mm in a Series A round co-led by SV Life Sciences and Polaris Venture Partners. Nonprofit organization Angeli Parvi, which provides seed financing to Dartmouth College entrepreneurial ventures, also participated. Partners from Polaris and SV Life Sciences joined Adimab's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adimab raises $6.2mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice